Klinisk Biokemi i Norden · 1 2014
| 13
U-M protein
type
P-M protein
Kvantitering
FLC§
+
+
+ (og symptomer)
(+)
+
+
+
+
+
+
(+)
+
+
+
+
+
+
+
+
+
+
*
+
+
+
+
+
(+)
+
+
+
+
+
+
(+)
+(IF negative)
+(IF negative)
+(>=90% reduction eller < 200 mg/24 timer)
+(<100 mg/24 timer)
+(0 g/l)
+(0 g/l)
+(>=25% stigning og >= 200 mg/d)
(+)#
+(normal k/l ratio)
Referencer
1. Criteria for the classification of monoclonal
gammopathies, multiple myeloma and related
disorders: a report of the International Myeloma
Working Group. Br J Haematol 2003;121:749-57.
2. Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, et al.: International sta-
ging system for multiple myeloma. J Clin Oncol
2005;23:3412-20.
3. Durie BGM, Salmon SE: A clinical staging system
for multiple myeloma. Cancer 1075;36:842-54.
4. Durie BG, Harousseau JL, Miguel JS, Bladé J,
Barlogie B, Anderson K, et al.: International
uniform response criteria for multiple myeloma.
Leukemia 2006;20:1467-73.
5. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ,
Buadi F, Dingli D, et al.: Importance of achiev-
ing stringent complete response after autologous
stem-cell transplantation in multiple myeloma. J
Clin Oncol, 2013 Nov 18. [Epub ahead of print]
* Ved genkomst M-komponent eller lille rest M-komponent bør typning dokumentere, at der er tale om den oprindelige
M-komponent
§ FLC kan anvendes til monitorering af patienter i stedet for U-M-komponent, som dog er nødvendig for respons evaluering
# Ved non-sekretorisk myelomatose med abnorm kappa-lambda ratio defineres PR som >= 50% reduktion af differencen
mellem involveret og ikke involveret letkæde
